Skip to main
VCEL

Vericel (VCEL) Stock Forecast & Price Target

Vericel (VCEL) Analyst Ratings

Based on 4 analyst ratings
Strong Buy
Strong Buy 75%
Buy 25%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Vericel Corp's positive outlook is supported by its projected revenue growth, with an estimated increase of 26% quarter-over-quarter for 4Q25, translating to approximately $84.8 million. The company's MACI product line is anticipated to experience volume growth in the low-to-mid teens, along with an estimated 21.2% year-over-year growth for FY26, driven by an average conversion rate of about 31.6% of biopsies to MACI. Additionally, the annual increase in average selling prices (ASPs) for MACI, projected to rise between 300 to 500 basis points, further underpins the company's sustainable revenue growth trajectory.

Bears say

Vericel Corp faces a negative outlook primarily due to lowered revenue expectations for its MACI product in fiscal years 2026 and 2027, with a reduction of approximately 200 basis points. Additionally, there are significant risks related to slower adoption rates for MACI and MACI Arthro, as well as challenges in burn care sales and potential disruptions stemming from sales force expansion. If the company fails to meet top-line expectations in any given quarter, it may result in shares dropping to historically low valuation points.

Vericel (VCEL) has been analyzed by 4 analysts, with a consensus rating of Strong Buy. 75% of analysts recommend a Strong Buy, 25% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Vericel and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Vericel (VCEL) Forecast

Analysts have given Vericel (VCEL) a Strong Buy based on their latest research and market trends.

According to 4 analysts, Vericel (VCEL) has a Strong Buy consensus rating as of Dec 30, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $57.50, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $57.50, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Vericel (VCEL)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.